Drifting of heme-coordinating group in imidazolylmethylxanthones leading to improved selective inhibition of CYP11B1
摘要:
An abnormal increase in glucocorticoid levels is responsible for pathological disorders affecting different organs and systems, and the selective inhibition of appropriate steroidogenic enzymes represents a validated strategy to restore their physiological levels. In continuing, our studies on CYP11B inhibitors, in this paper a small series of 6-substituted 3-imidazolylmethylxanthones was designed and synthesized, according to the data acquired from previously reported series of derivatives and from a purposely-performed docking study. The new compounds proved to be potent inhibitors of CYP11B isoforms, being effective on CYP1161 in the low nanomolar range and improving selectivity with respect to CYP11B2, compared to previously reported related compounds. These data further confirmed that a suitable mutual arrangement of the imidazolylmethyl pharmacophore and a properly selected substituent on the xanthone core allows a fine tuning of the activity towards the different CYPs and further corroborate the role of the xanthone scaffold as a privileged structure in this field. (C) 2017 Elsevier Masson SAS. All rights reserved.
转甲状腺素蛋白是一种四聚体蛋白,其功能是作为甲状腺素和视黄醇结合蛋白的转运蛋白。已知转甲状腺素蛋白的错误折叠和淀粉样蛋白聚集会导致野生型和遗传性转甲状腺素蛋白淀粉样变性。通过低分子量化合物稳定转甲状腺素蛋白四聚体是抑制淀粉样变性聚集途径的有效策略。在这里,我们研究了蒽醌和氧杂蒽酮衍生物对淀粉样蛋白聚集的抑制活性,发现具有一个氯或甲基的氧杂蒽酮-2-羧酸具有与二氟尼柳相当的强抑制活性,二氟尼柳是最著名的稳定剂之一。转甲状腺素蛋白。与化合物复合的转甲状腺素蛋白的 X 射线晶体结构表明,引入氯、它被埋在疏水区域中,对于稳定剂对淀粉样变性的强抑制作用很重要。一个体外吸收、分布、代谢和消除 (ADME) 研究和体内药代动力学研究表明,这些化合物具有类似药物的特性,表明它们具有作为稳定转甲状腺素蛋白的治疗剂的潜力。